Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P

Pharmacotherapy6 Jun 2013Cited by 29 (Europe PMC)

PMID23744726DOI10.1002/phar.1301PepBankPUB-23744726

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with diabetes on metformin, exenatide improved HbA1c more than placebo.
In plain wordsIn adults with diabetes on metformin, exenatide improved HbA1c more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
HbA(1c) was significantly improved with exenatide plus metformin compared with placebo plus metformin.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472601
02HumanRandomized controlled trialEfficacy outcome
In adults with diabetes on metformin, exenatide increased HOMA-β C-peptide more than placebo.
In plain wordsIn adults with diabetes on metformin, exenatide increased HOMA-β C-peptide more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHOMA-β C-peptide
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-β C-peptide, and all measures of β-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472602
03HumanRandomized controlled trialEfficacy outcome
In adults with diabetes on metformin, exenatide increased clamp measures of β-cell function more than placebo.
In plain wordsIn adults with diabetes on metformin, exenatide improved clamp measures of insulin-producing cell function more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseClamp β-cell function measures
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-β C-peptide, and all measures of β-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472604
04HumanRandomized controlled trialEfficacy outcome
In adults with diabetes on metformin, exenatide reduced resistin compared with placebo.
In plain wordsIn adults with diabetes on metformin, exenatide reduced resistin compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseResistin
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472605
05HumanRandomized controlled trialEfficacy outcome
In adults with diabetes, vaspin did not differ between exenatide plus metformin and placebo plus metformin.
In plain wordsIn adults with diabetes on metformin, vaspin did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeVaspin
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
No variations in vaspin and chemerin were noted in group-to-group comparisons.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472606
06HumanRandomized controlled trialEfficacy outcome
In adults with diabetes, chemerin did not differ between exenatide plus metformin and placebo plus metformin.
In plain wordsIn adults with diabetes on metformin, chemerin did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeChemerin
Study
n = 174
Comparator
Placebo plus metformin
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter · 12 monthsAs given in this study (human).
Source sentences
Summary
No variations in vaspin and chemerin were noted in group-to-group comparisons.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
Report a problemFND-2374472607

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In the exenatide plus metformin group, increased M value correlated with decreased inflammatory parameters.
In plain wordsIn the exenatide plus metformin group, improved insulin sensitivity was linked to lower inflammatory markers.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableInsulin sensitivity and inflammation correlation
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled trial.
Summary · context
A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%.
Summary · context
After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2374472608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.